Fresenius Medical Care (NYSE:FMS) Now Covered by Analysts at StockNews.com

Research analysts at StockNews.com started coverage on shares of Fresenius Medical Care (NYSE:FMS) in a research report issued to clients and investors on Monday. The brokerage set a “strong-buy” rating on the stock.

Separately, Truist Financial reduced their target price on Fresenius Medical Care from $24.00 to $22.00 and set a “hold” rating for the company in a research note on Wednesday, July 31st. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, one has issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $22.00.

Fresenius Medical Care Price Performance

Fresenius Medical Care stock opened at $21.31 on Monday. Fresenius Medical Care has a 52 week low of $16.37 and a 52 week high of $22.76. The company has a quick ratio of 1.09, a current ratio of 1.46 and a debt-to-equity ratio of 0.45. The firm’s 50-day simple moving average is $19.67 and its 200 day simple moving average is $19.95. The firm has a market capitalization of $12.51 billion, a PE ratio of 23.94, a P/E/G ratio of 1.08 and a beta of 0.90.

Fresenius Medical Care (NYSE:FMS) last announced its earnings results on Tuesday, July 30th. The company reported $0.38 earnings per share for the quarter, meeting the consensus estimate of $0.38. Fresenius Medical Care had a net margin of 2.72% and a return on equity of 5.48%. The firm had revenue of $5.13 billion during the quarter, compared to the consensus estimate of $5.28 billion. On average, equities research analysts predict that Fresenius Medical Care will post 1.51 EPS for the current fiscal year.

Institutional Trading of Fresenius Medical Care

Several large investors have recently added to or reduced their stakes in FMS. Mercer Global Advisors Inc. ADV increased its position in shares of Fresenius Medical Care by 4.5% during the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 14,581 shares of the company’s stock worth $278,000 after purchasing an additional 624 shares in the last quarter. Signaturefd LLC raised its holdings in shares of Fresenius Medical Care by 8.4% in the second quarter. Signaturefd LLC now owns 8,713 shares of the company’s stock valued at $166,000 after purchasing an additional 672 shares during the last quarter. GAMMA Investing LLC raised its holdings in shares of Fresenius Medical Care by 21.8% in the first quarter. GAMMA Investing LLC now owns 4,230 shares of the company’s stock valued at $82,000 after purchasing an additional 758 shares during the last quarter. Ritholtz Wealth Management grew its stake in shares of Fresenius Medical Care by 2.5% in the second quarter. Ritholtz Wealth Management now owns 36,901 shares of the company’s stock valued at $704,000 after buying an additional 895 shares in the last quarter. Finally, Rhumbline Advisers grew its stake in shares of Fresenius Medical Care by 6.7% in the second quarter. Rhumbline Advisers now owns 18,067 shares of the company’s stock valued at $345,000 after buying an additional 1,128 shares in the last quarter. 8.25% of the stock is owned by institutional investors.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.